Navigation Links
Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
Date:1/11/2012

f cancer by successfully driving its pipeline of antibody-based therapeutics into the clinic."

Dr Christian Rohlff, CEO of OBT, commented, "I am delighted to welcome Glenn to OBT.  His wealth of relevant clinical and commercial expertise in the oncology and antibody field will be instrumental in helping OBT to transition into a successful clinical development organisation as the company works to enhance the future treatment prospects for cancer patients with no treatment."

Today's announcement follows OBT's recent collaboration with Seattle Genetics, Inc. for the development of antibody drug conjugates (ADCs) for cancer, highlighting OBT's growing recognition in the ADC field.  

About OGAP®

The Oxford Genome Anatomy Project (OGAP®) database represents one of the world's largest proprietary collections of disease-associated proteins. OGAP® oncology contains proteomic data on over 7,500 cancer membrane proteins combined with genomic and clinical information derived from human blood and cancer tissue studies. OGAP® contains proprietary target information on three-quarters of the entire human proteome. Almost two million human protein fragments have been sequenced in OGAP® in 50 different human tissues representing 60 diseases, including 25 forms of cancer. OGAP® integrates data covering 17,000 different genes and over eight million genetic variants (SNPs and haplotypes).

About Oxford BioTherapeutics

Oxford BioTherapeutics (OBT) is a leading international biotechnology company focused on the development and commercialization of innovative antibody-based cancer medicines, with integrated diagnostics, against novel targets that it has discovered in its unique OGAP® proteomic database. OBT accesses leading antibody technologies and expertise through its partnerships with many of the world leaders in antibody development, including BMS (Medarex), Amgen, Alere (formerly Biosite) and BioWa,
'/>"/>

SOURCE Oxford BioTherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oxford BioMedica Announces US IND Approval for Novel Ocular Product in Usher Syndrome Type 1B
2. CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics
3. Oxford BioMedica Announces 5T4 Antibody Research Collaboration with ImaginAb
4. Oxford Finance Corporation Sponsors 2010 Mid-Atlantic Bio
5. Oxford Resource Partners, LP and Mendel Biotechnology, Inc. Announce a Miscanthus Biomass Pilot Project in Ohio
6. Oxford Finance Corporation Hires Dr. Killu Sanborn to Support Life Science Business Development in Western North America
7. ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis
8. Oxford BioTherapeutics Appoints Michael Moore as Chairman
9. Oxford Performance Materials Introduces OXPEKK PermettaTM High Performance Polymer Films
10. TED Conferences Announces 25 TED Fellows for TEDGlobal in Oxford
11. The Court Supports Bavarian Nordics Decision to Start Patent Infringement Case Against Oxford BioMedica
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... The identification of protein-coding variants ... accelerated by exome sequencing. Built on Roche NimbleGen’s ... SeqCap EZ Developer system has been a proven ... additionally present how he achieved coverage statistics similar ... mouse exome kits. With over 236,000 SNPs and ...
(Date:8/22/2014)... 22, 2014 “Our nation's healthcare ... a national disgrace. Furthermore, every governmental and professional ... current, deplorable state of unorganized dysfunction shares in ... to merely serve as a device to use ... colossal failure(s) that have accumulated through the years ...
(Date:8/21/2014)... 21, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... in class collagenase-based products marketed as XIAFLEX ® ... U.S. and XIAPEX ® in the EU, ... randomized, double-blind Phase 2a study of CCH for ... panniculopathy. The results showed that all three doses ...
(Date:8/21/2014)... 21, 2014 DNA vaccine pioneer ... its development of JRC-LAMP-vax, an innovative and safe potential ... IC studies began this month in Hawaii, moving the ... , The Japanese red cedar releases pollen that causes ... Mountain Cedar pollen wreaks similar havoc in Colorado, New ...
Breaking Biology Technology:Efficient Identification of Protein-Coding Variants in a Model Organism Through Exome Sequencing, New Webinar Hosted by Xtalks 25 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4
... Exchange Symbol: MS, EDMONTON, June 18 /PRNewswire-FirstCall/ - ... treatment of multiple sclerosis (MS), today,announced that Mr. Kevin ... Annual Healthcare Conference in New York., WHEN: ... WHERE: Mandarin Oriental, New York, About ...
... Response Prediction to Ovarian Cancer Treatment, Predicting ... Small Cell From Non-Small Cell Lung Cancer, In Addition, the Company has ... may Serve as the Basis for a Future ... Test for Colon Cancer, ...
... Experienced Biotech Business Development and Investment Banker Enhances ... EntreMed,s Senior Management Team, ... ), a clinical-stage pharmaceutical company developing,therapeutics for the treatment of ... H. Bliss, Jr. as Senior Vice,President, Corporate and Business Development. ...
Cached Biology Technology:BioMS Medical to present at Jefferies Healthcare Conference 2Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development 2Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development 3Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development 4Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development 5EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development 2EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development 3EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development 4
(Date:8/21/2014)... , Saturday to Wednesday, Oct. 18-22, 2014 , ... W. Harbor Drive, San Diego, CA 92101 , ... and other presentations of the latest research in ... plenary session featuring high-scoring abstracts on rare genetic ... various cancers, and treatment for sun sensitivity (Saturday, ...
(Date:8/21/2014)... (ANU) team has successfully replicated one of the crucial ... powered by sunlight which could manufacture hydrogen as a ... It is an exciting prospect to use them to ... Dr Kastoori Hingorani, from the ARC Centre of Excellence ... Biology. , Hydrogen offers potential as a zero-carbon replacement ...
(Date:8/20/2014)... of 158 pregnant teenagers in Rochester, NY, nearly half ... of ice, cornstarch, vacuum dust, baby powder and soap, ... , Moreover, such teens had significantly lower iron levels ... substances. , Pregnant teens, regardless of pica, are at ... iron deficiency and anemia. Low iron in pregnant teens ...
Breaking Biology News(10 mins):American Society of Human Genetics 2014 Annual Meeting 2Water and sunlight the formula for sustainable fuel 2Pica in pregnant teens linked to low iron 2
... St. Paul, Minn. (August 26, 2009)-The American Phytopathological Society ... 2009 awards. The awards were presented during the APS ... held August 1-5, in Portland, Oregon. The ... in recognition of distinguished contributions to plant pathology or ...
... Genome Project an explosion of data has sent the science ... codes, which list the "ingredients for life," but do not ... Rutgers UniversityCamden biochemist is addressing this knowledge gap through the ... known enzyme functions. Thanks to a National Institute of ...
... viral polymerase may provide a new therapeutic target for host-adapted ... "Spread of Infection and Lymphocyte Depletion in Mice Depends on ... of the American Journal of Pathology . Highly ... strain of the influenza virus that has adapted to infect ...
Cached Biology News:The American Phytopathological Society announces 2009 awardees 2Rutgers-Camden developing enzyme function database 2
... Channel Cell Lines ,High Quality, Functionally-Validated, Ion ... well known for having a critical role ... have a key function in pain, CNS ... channels have been investigated in therapeutic areas, ...
Mouse polyclonal antibody raised against a partial recombinant CD320. NCBI Entrez Gene ID = 51293...
Mouse monoclonal antibody raised against a partial recombinant CHD8. NCBI Entrez Gene ID = CHD8...
Mouse monoclonal antibody raised against a partial recombinant DENR. NCBI Entrez Gene ID = DENR...
Biology Products: